Effects of a single treatment with two nonthermal laser wavelengths on chronic neck and shoulder pain
Authors Silverman RG, Comey A, Sammons T
Received 7 June 2019
Accepted for publication 2 August 2019
Published 30 August 2019 Volume 2019:12 Pages 319—325
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Dr Scott Fraser
Robert G Silverman,1 Albert Comey,2 Travis Sammons3
1Clinical Study Site, New York ChiroCare, White Plains, NY, USA; 2Clinical Study Site, Comey Chiropractic Clinic, Largo, FL, USA; 3Erchonia Corporation, Melbourne, FL, USA
Correspondence: Travis Sammons
Erchonia Corporation, 650 Atlantis Road, Melbourne, FL 32904, USA
Tel +1 321 473 1251
Fax +1 321 473 1608
Introduction: Nonthermal lasers provide pain relief for a variety of musculoskeletal disorders and improve physical functioning. A nonthermal laser that employs a 635 nm red diode is cleared for the temporary reduction of neck and shoulder pain of musculoskeletal origin. As a 405 nm violet laser has shown synergy with the 635 nm red laser when used together for treating other conditions, the objective of this study was to compare the efficacy of 635 nm red and 405 nm violet lasers vs the 635 nm red laser for treating neck and shoulder pain of musculoskeletal origin.
Materials and methods: Otherwise healthy adult subjects with chronic neck or shoulder pain for ≥30 days were enrolled and randomized to receive a single 13-min treatment with combined red and violet lasers (n=44) or the red laser alone (n=43). The primary efficacy measure was change in baseline VAS pain scores 3 mins after treatment. Subject success was predefined as a ≥30% decrease in VAS scores and study success was predefined as 65±5% individual subject successes.
Results: Among subjects treated with the red and violet lasers, mean VAS neck and shoulder pain scores decreased from 65.0 to 35.2 (p<0.0001). Most subjects in the study (75%) achieved ≥30% decrease in VAS scores. The decreased mean (SD) VAS scores remained 29.6 (16.7) and 29.3 (19.2) after 24 and 48 hrs, respectively. The secondary efficacy measures of change in range of motion ROM) and patient satisfaction also improved. There were no adverse events.
Conclusion: Overall, treatment with the red and violet lasers outperformed the FDA-approved red laser with respect to change in pain scores and improvement in shoulder ROM.
Keywords: nonthermal laser, low-level laser, chronic pain, randomized trial
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]